Abstracts tagged "fibromyalgia and systemic lupus erythematosus (SLE)"

Abstract Number: 239 • 2019 ACR/ARP Annual Meeting
The SELENA SLEDAI Is an Imperfect Measure of Lupus Disease Activity in Patients with Concomitant Fibromyalgia
Robert Katz¹, Jessica Polyak Wokurka ² and Ben Small ², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: The SELENA-SLEDAI is a tool for measuring the activity of systemic lupus. It is frequently used in clinical drug trials, but what is the…
Abstract Number: 1986 • 2017 ACR/ARHP Annual Meeting
Using the BILAG to Assess the Activity of Lupus in Patients with Fibromyalgia
Robert S. Katz¹, Jessica L. Polyak² and Frank Leavitt¹, ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates S.C., Chicago, IL
Background/Purpose: The BILAG is often used to assess the efficacy of lupus treatments, and is a commonly used tool in lupus drug trials. But the…
Abstract Number: 3087 • 2015 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products in Multianalyte Assay with Algorithm Have Utility in Distinguishing Primary Fibromyalgia from Systemic Lupus Erythematosus
Daniel Wallace¹, Stuart L. Silverman², Derren Barken³, John Conklin⁴ and Thierry Dervieux⁵, ¹Cedars-Sinai/UCLA, Los Angeles, CA, ²OMC Clinical Research Center, Beverly Hills, CA, ³Exagen Diagnostics, Vista, CA, ⁴1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose : Our objective was to prospectively establish the performance characteristics of a cell bound complement activation products (CB-CAPS) in a multi-analyte assay with algorithm…
Abstract Number: 1878 • 2012 ACR/ARHP Annual Meeting
Cognitive Manifestations of Fibromyalgia and Lupus
Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL
Background/Purpose: Similar cognitive complaints for patients with fibromyalgia and systemic lupus erythematosus (SLE) have been reported; however, inherently different deficits can share superficial similarities. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].